气相色谱电子捕获检测法测定人尿中氟硝西泮的代谢物7-氨基氟硝西泮

采用气相色谱电子捕获检测法测定人尿中氟硝西泮的代谢物 7 氨基氟硝西泮。测定时尿中加入内标 7 氨基硝西泮 ,用β 葡萄糖醛酸苷酶水解及碱性液液萃取 ,再用七氟丁酸酐衍生化。尿中 7 氨基氟硝西泮提取率为 96.8% ;回收率为 98.6± 3 .4% (平均值±SD) ;检出限为 1 .2 μg L ,对口服治疗量氟硝西泮的人尿进行检测 ,可检出服药后 60h尿中的 7 氨基氟硝西泮。     

尿中氯硝西泮代谢物7-氨基氯硝西泮的薄层色谱检测法

采用高效薄层色谱法检测尿中氯硝西泮代谢物7－氨基氯硝西泮（7ACLZ），分析物斑点用弗路兰进行荧光显现，灵敏度高，检出限5μg/L，定量下限15μg/L，可以检测人口服2mg氯硝西泮后48h内排泄尿的7ACLZ,适用于麻醉抢劫犯罪案件中药物检测。     

特丁基二甲基硅烷衍生化-气相色谱-质谱联用法分析尿中硝西泮的代谢物7-氨基硝西泮

建立了用特丁基二甲基硅烷(TBDMS)衍生化-气相色谱-质谱联用分析尿中硝西泮的主要代谢物7-氨基硝西泮(7ANIZ)的高灵敏方法。方法的样品萃取率为83．6％；线性范围为10～500μg/L；检出限(LOD)为1μg/L;定量限(LOQ)为3μg/L；RSD为3．6％-5．8％，回收率为96．3％-102．6％。对口服10mg硝西泮者96h内所排泄的尿液进行了7ANIZ检测，结果表明：本方法能满足司法鉴定的要求。     

三甲基硅烷衍生化-气相/质谱联用法分析尿中7-氨基硝西泮

 建立了分析尿中硝西泮主要代谢物 7 氨基硝西泮 (7 ANIZ)的三甲基硅烷衍生化 气相 /质谱联用方法。尿样经乙醚 乙酸乙酯 (体积比为 99∶1 )萃取后 ,用N ,O 双 (三甲基硅 )三氟乙酰胺进行衍生化 ,检测衍生物的总离子流。根据 7 ANIZ衍生物质谱中主要特征离子的相对丰度及其质量的保留时间进行定性分析 ;用 7 氨基氯硝西泮做内标 ,根据衍生物基峰离子的质量进行定量分析。本方法中 7 ANIZ的萃取率为 82 8% ,线性范围为 1 0 μg/L～ 50 0 μg/L,检出限为 1 2 μg/L,定量限为 3 5μg/L。     

血、尿中氯硝西泮及其代谢物7-氨基氯硝西泮的GC-ECD法检测

报道了血、尿中氯硝西泮及其代谢物7－氨基氯硝西泮的GC－ECD检测方法。苯－异戊醇碱性条件下（pH10.8）液－液萃取，灵敏度较高，氯硝西泮和7－氨基氯硝西泮的检测限（LOD）分别为3．2ng/mL及1．7ng/mL。线性范围5－300ng/mL，RSD5．3％。     

硝西泮、氯硝西泮甲基衍生物的气相色谱-质谱分析

对硝西泮和氯硝西泮的衍生化条件、色谱及质谱行为进行了研究,确立了猪肉中硝西泮、氯硝西泮残留的GC-MS检测方法.应用5因素4水平的正交试验,最终确定衍生化条件为反应温度60℃、反应时间30 min、丙酮用量0.5 mL、衍生化试剂20μL、催化剂无水碳酸钾20mg,在此条件下可生成较完全的甲基衍生物.衍生物具有较好的气相色谱和电子轰击质谱行为.硝西泮衍生物的分子离子峰为m/z 295,基峰离子为m/z 267,主要碎片离子分别为m/z 206、220、248、294;氯硝西泮衍生物的分子离子峰为m/z 329,基峰离子为m/z 328,主要碎片离子分别为m/z205、220、248、266、294、331,并对这些离子的产生进行了解析.这些离子均具有较强的相对丰度,可作为其微量检测的多离子选择定性和确证,而基峰离子可用于单离子选择定量.用乙腈提取药物,C18固相萃取柱净化,GC-MS分析.本方法采用外标法定量,两种药物的标准曲线线性回归系数均在0.99以上,线性范围20～500 μg/L,回收率80%左右,相对标准偏差6.9%～14.9%,检出限16.7 μg/kg.     

自动固相萃取/液相色谱-串联质谱法测定血液中氯硝西泮及其代谢产物7-氨基氯硝西泮

建立了血液中氯硝西泮及其代谢产物7-氨基氯硝西泮的自动固相萃取/液相色谱-串联质谱(ASPE/LC-MS/MS)分析方法。样品经C18固相萃取柱提取后,采用LC-MS/MS进行测定,外标法定量。在Waters Atlantis TM d C18反相柱上分离,梯度洗脱,流动相为甲醇和0.1%甲酸水溶液,质谱采集为电喷雾正离子多反应监测模式。2种目标物在2~1 000μg/L范围内具有良好的线性关系,相关系数为0.995 9~0.998 2,检出限为0.2~0.5μg/L;加标水平为50,200,1 000μg/L时,方法的回收率为72.6%~96.3%,相对标准偏差为4.2%~10.3%。本方法可用于法庭与临床的毒物分析。     

氟的单扫描极谱测定改进体系研究及分析应用

采用三电极系统, 在HCl条件下, 利用氟对锆(Ⅳ)-水杨基荧光酮(SAF)二元络合体系的竞争抑制及聚乙二醇的增敏作用, 用单扫描极谱法测定多样品中各含量的氟. 最佳底液组成是: 1.2 mg/L Zr(Ⅳ)-0.24 mol/L HCl-1.4×10-4 mol/L的水杨基荧光酮-1.6 mg/L的聚乙二醇(20000). 其起始电位为-0.30 V, 峰电位在-0.68 V (vs. SCE)左右, 测氟的线性范围为16.0～800.0 μg/L, 线性回归方程为Ip″(×10-4 nA)＝1.3551+0.0048c (μg/L) (n＝21, r＝0.9996), 检出限为12.2 μg/L. 本法适用于土壤、水样、蔬菜及人发中各含量氟的测定. 用单扫描极谱法研究了氟的极谱行为, 证明了电极反应物为水杨基荧光酮而非ZrFp4-p, 极谱波为不可逆还原吸附波, 讨论了电极反应机理.     

顶空气相色谱法测定氟尼辛葡甲胺原料药中有机溶剂残留量

建立了氟尼辛葡甲胺原料药中乙酸乙酯、甲醇、异丙醇、乙醇和乙腈有机溶剂残留量的顶空气相色谱分析方法。以HP-FFAP色谱柱(30 m×0.32 mm×1.0 μm)为分离柱,火焰离子化检测器检测,外标法定量,并考察了顶空平衡温度、平衡时间等对残留有机溶剂测定的影响。实验结果表明,在顶空平衡温度为90 ℃、平衡时间为30 min条件下获得较好的定量结果。乙酸乙酯、甲醇、异丙醇、乙醇和乙腈的线性范围分别为0.40～7.93 mg/L (r=0.9998)、7.32～146.48 mg/L (r=0.9996)、4.53～90.61 mg/L (r=0.9999)、3.62～72.32 mg/L (r=0.9998)和2.31～46.24 mg/L (r=0.9996);平均回收率范围为95.96%～100.31%,精密度(以相对标准偏差计,n=6)为1.97%～3.28%;检出限分别为0.08、0.9、0.2、0.4和0.3 mg/L。利用该方法对实际样品氟尼辛葡甲胺原料药中有机溶剂残留量进行了检测。结果表明,该样品中含有异丙醇和乙醇,其含量分别为177.44 μg/g与69.32 μg/g。本方法快速、灵敏、准确,适用于氟尼辛葡甲胺原料药中残留溶剂的检测。     

单扫描极谱法测定土壤、蔬菜、水样中痕量氟

本文采用三电极系统,在0.08mol/L盐酸条件下,利用氟对锆(-水杨基荧光酮(SAF)-十六烷基三甲基溴化铵(CTMAB)三元络合体系的竞争抑制,用单扫描极谱法测定多样品中的痕量氟。最佳底液条件是:0.8mg/LZr(-1.4×10-4mol/L(SAF)-8.0×10-6mol/L(CTMAB)。其起始电位为-0.25V,峰电位在-0.65V(vs.SCE)左右,测氟的线性范围为40～640μg/L。检出限为2.0μg/L。本方法具有反应快、重现性好、检测灵敏、选择性好、操作方便的特点。本法适用于土壤,水样及蔬菜中微量氟的测定。用单扫描极谱法研究了氟的极谱行为,证明了该波为不可逆还原吸附波,讨论了电极反应机理。     

Sweeping technique combined with micellar electrokinetic chromatography for the simultaneous determination of flunitrazepam and its major metabolites

A sweeping technique, in conjunction with micellar electrokinetic chromatography, for the simultaneous determination of flunitrazepam and its major metabolites, 7-aminoflunitrazepam and N-desmethylflunitrazepam, is described. The optimized conditions for the sweeping and separation were a pH 9.5 buffer, 25mM borate, 50mM cetyltrimethylammonium bromide, 30% MeOH (v/v), and a 151-mm injection length. The calibration functions were all linear with the coefficient of determination (r(2)) exceeding 0.996 for the three target compounds. Using the sweeping procedure, the limits of detection were determined to be 13.4, 5.6, and 12.0ng/mL for flunitrazepam, 7-aminoflunitrazepam, and N-desmethylflunitrazepam, respectively, and the sensitivity enhancement for each compound was within the range of 110-200 fold. The RSDs for the retention time and the peak area were less than 4.10%. The optimized sweeping method was also used to examine a spiked urine sample. We conclude that sweeping with micellar electrokinetic chromatography has considerable potential use in clinical and forensic analyses of flunitrazepam and its metabolites.     

Determination of flunitrazepam and 7-aminoflunitrazepam in human urine by on-line solid phase extraction liquid chromatography-electrospray-tandem mass spectrometry

A method using an on-line solid phase extraction (SPE) and liquid chromatography with electrospray-tandem mass spectrometry (LC-ES-MS/MS) for the determination of flunitrazepam (FM2) and 7-aminoflunitrazepam (7-aminoFM2) in urine was developed. A mixed mode Oasis HLB SPE cartridge column was utilized for on-line extraction. A reversed phase C₁₈ LC column was employed for LC separation and MS/MS was used for detection. Sample extraction, clean-up and elution were performed automatically and controlled by a six-port valve. Recoveries ranging from 94.8 to 101.3% were measured. For both 7-aminoFM2 and FM2, dual linear ranges were determined from 20 to 200 and 200-2000 ng/ml, respectively. The detection limit for each analyte based on a signal-to-noise ratio of 3 ranged from 1 to 3 ng/ml. The intra-day and inter-day precision showed coefficients of variance (CV) ranging from 4.6 to 8.5 and 2.6-9.2%, respectively. The applicability of this newly developed method was examined by analyzing several urine samples.     

Determination of 7-aminoflunitrazepam in urine by dispersive liquid-liquid microextraction with liquid chromatography-electrospray-tandem mass spectrometry

Dispersive liquid-liquid microextraction (DLLME) and liquid chromatography-electrospray-tandem mass spectrometry (LC-ES-MS/MS) procedure was presented for the extraction and determination of 7-aminoflunitrazepam (7-aminoFM2), a biomarker of the hypnotic flunitrazepam (FM2) in urine sample. The method was based on the formation of tiny droplets of an organic extractant in the sample solution using water-immiscible organic solvent [dichloromethane (DCM), an extractant] dissolved in water-miscible organic dispersive solvent [isopropyl alcohol (IPA)]. First, 7-aminoFM2 from basified urine sample was extracted into the dispersed DCM droplets. The extracting organic phase was separated by centrifuging and the sedimented phase was transferred into a 300 μl vial insert and evaporated to dryness. The residue was reconstituted in 30 μl mobile phase (20:80, acetonitrile:water). An aliquot of 20 μl as injected into LC-ES-MS/MS. Various parameters affecting the extraction efficiency (type and volume of extraction and dispersive solvent, effect of alkali and salt) were evaluated. Under optimum conditions, precision, linearity (correlation coefficient, r² = 0.988 over the concentration range of 0.05-2.5 ng/ml), detection limit (0.025 ng/ml) and enrichment factor (20) had been obtained. To our knowledge, DLLME was applied to urine sample for the first time.     

Gas chromatographic determination of bromo and fluoro derivatives of benzodiazepine in human body fluids

A rapid, sensitive and accurate method for the determination of bromazepam and flunitrazepam in plasma and urine using gas chromatography has been developed. Bromazepam was extracted with diethyl ether and flunitrazepam with hexane at pH 7. A nitrogen detector was used to determine bromazepam and an electron-capture detector was used for flunitrazepam.     

Determination of malotilate and its metabolites in plasma and urine

A method for the determination of malotilate (I), the corresponding monocarboxylic acid (II) and its decarboxylated product (III) in plasma is described. Plasma was extracted with chloroform spiked with internal standard. The residue, dissolved in methanol, was chromatographed on a reversed-phase column with a mobile phase of 60% acetonitrile and 1% acetic acid in water. The sensitivity limit for I, II and III was 50, 25 and 100 ng/ml of plasma, respectively. Compound I in the same plasma extract was also analysed by gas chromatography--electron-impact mass spectrometry. The base peaks m/z 160 for I and m/z 162 for internal standard (IV) were monitored; the sensitivity limit for I was 2.5 ng/ml of plasma. The determination of the metabolites of I, II and its conjugate (V), and isopropyl-hydrogen malonate (VI) in urine by high-performance liquid chromatography is also described. The limit of quantification for VI was 2.0 micrograms/ml, and the overall coefficient of variation of VI was 4.7%. The limit of quantification for II in urine was 0.5 micrograms/ml and that for V was 1.0 micrograms/ml as total II (II + V). The overall precision of the method was satisfactory. The method was used to determine plasma and urine concentrations in four dogs orally dosed with 100, 200 or 400 mg of malotilate.     

Simple high-performance liquid chromatographic method for the determination of a new phytochemical drug, fellavine, and its metabolites in human and rat plasma and urine.

The use of a small precolumn instead of an injection loop for the determination of a new phytochemical drug, fellavine, and its metabolites is described. The method combines the direct injection of plasma and urine into the reversed-phase precolumn with separation on a Spheri-5 RP-18 analytical column. Different sorbents in the precolumn were compared. A recovery of fellavine and its metabolites from biological fluids except rat plasma of almost 100% was achieved on Chrompack RP (30-40 microns) and LiChrosorb RP-18 (7 microns). For rat plasma only the last sorbent gave 80% fellavine recovery. The influence of the protein binding on the fellavine recovery was examined. The limit of detection was equal to 0.05 micrograms/ml fellavine for plasma and 0.02 micrograms/ml for urine. To enhance the limit of detection longer precolumns were perferred.     

Chromatographic determination of amines in biological fluids with special reference to the biological monitoring of isocyanates and amines. IV. Determination of 1,6-hexamethylenediamine in human urine using capillary gas chromatography and selective ion monitoring

A capillary gas chromatographic (GC) method was developed for the determination of 1,6-hexamethylenediamine (HDA) in hydrolysed human urine. The method was based on a derivatization procedure with heptafluorobutyric anhydride. The amides formed were determined using capillary GC with selected ion monitoring in the chemical ionization mode with ammonia as reagent gas. The overall recovery was 34% for a concentration of 100 micrograms/l of HDA in urine. The minimum detectable concentration in urine was below 0.5 microgram/l. The precision of the method was 5% (n = 9). Deuterium-labelled HDA [H2NC2H2(CH2)4C2H2NH2] was used as the internal standard. A male subject was exposed to hexamethylene diisocyanate (HDI) for 7.5 h in a test chamber. The average air concentration of HDI was ca. 30 micrograms/m3, which corresponds to ca. 85% of the threshold limit value in Sweden (35 micrograms/m3). The half time of urinary levels of HDA was ca. 1.4 h and more than 90% of the urinary elimination was completed within 4 h after the exposure. The amount of HDA excreted in urine was ca. 10 micrograms, corresponding to ca. 10% of the estimated inhaled dose of HDI.     

Sensitive gas chromatographic--mass spectrometric screening of acetylated benzodiazepines

GC-MS screening conditions were developed for 15 low-dosed benzodiazepines, covering alprazolam, flunitrazepam, flurazepam, ketazolam, lorazepam and triazolam, and the corresponding metabolites alpha-hydroxyalprazolam, 4-hydroxyalprazolam; 7-aminoflunitrazepam, desmethylflunitrazepam, 7-aminodesmethylflunitrazepam; hydroxyethylflurazepam, N-desalkylflurazepam; oxazepam and alpha-hydroxytriazolam, respectively. Benzodiazepines are analyzed on a polydimethylsiloxane column in both the scan and the multiple ion monitoring modes using on-column injection to attain maximal sensitivity. The reactive compounds are acetylated with pyridine and acetic anhydride for 20 min. The derivatives are stable for at least 4 days. The relative standard deviation observed with standard compounds at the low nanogram-level ranged from 1.13 to 4.87% within-day and from 1.12 to 4.94% between-day. Unequivocal identification potential, high chromatographic resolution and sensitivity are combined with minimal thermal degradation. The presented screening conditions provide the basis for a unique routine screening method for low-dosed benzodiazepines with a broad polarity range.     

Analytical procedure for the determination of rufloxacin, a new pyridobenzothiazine, in human serum and urine by high-performance liquid chromatography

A high-performance liquid chromatographic method for the quantification of rufloxacin in human serum and urine has been developed and validated. The compounds, rufloxacin and internal standard, are extracted from buffered serum and urine using dichloromethane. They are then separated on an anion-exchange column using 0.05 M phosphate buffer-acetonitrile (80:20, v/v). The eluate is quantified by measuring the ultraviolet absorbance at 296 nm. The lower limit of detection for the analyte is 0.1 microgram/ml in serum and 0.05 micrograms/ml in urine. The method is linear from 0.3 to 10 micrograms/ml for serum and 0.1 to 10 micrograms/ml for urine. The method has been applied in a pharmacokinetic study in volunteers.